Abstract 1098P
Background
Neoadjuvant therapy (NAT) with immunotherapy (anti-PD1-based) has shown promising event-free survival (EFS) and pathologic complete response (pCR) in resectable melanoma patients. We performed a systematic review and meta-analysis to evaluate anti-PD1-based NAT for stage III and IV resectable melanoma.
Methods
We searched PubMed, Scopus, and Cochrane Library databases for clinical trials and observational cohort studies. Outcomes of interest were pCR, major pathologic response (MPR), EFS, and overall survival (OS). Subgroups analysis included clinical stages and mucosal and acral melanomas (MM/AM) subpopulation. Heterogeneity was examined with I2 statistics; We used a DerSimonian and Laird random effects model.
Results
Eleven studies were included, comprising nine phase II/Ib clinical trials and two observational cohort studies with 486 patients. Of them, 85% had cutaneous melanoma, and 15% had MM/AM. Overall, 43% received single-agent NAT. In a pooled analysis, the pCR rate was 35.1% (95%CI 25.7-44.4). Stage III patients achieved a pCR of 36.9% (95%CI 28.9-71.5), whereas studies including stages III/IV reported pCR in 34.1% (95%CI 19.9-48.4). Single-agent therapy led to pCR in 30.5% (95%CI 20.2-40.9) of patients, while those treated with combination therapy had a pCR rate of 42.1% (95%CI 25.6-58.5). MPR was reached in 49.0% (95% 39.6-58.5) of patients. 231 (82.4%) remained free-of-events with a minimum follow-up of 14.6 months. OS was 90.1% (95%CI 86.0-93.1) in two years (27 deaths). Overall pathological response (CR+MPR+PR) was seen in 71.2% (95%CI 63.5-79.0) of patients, and the overall radiographic response in 50.8% (95%Cl 45.0-56.5). According to pCR, responders had a greater EFS than non-responders with an OR of 0.10 (95%CI 0.02-0.49 p=0.004). Among MM/AM, 19.9% (95%CI 7.8-34.9) of patients had pCR. There were no treatment-related deaths or delays of surgery.
Conclusions
Our study supports anti-PD1-based NAT anti-tumor activity in patients with resectable melanoma. Patients with pCR and stage III seem to benefit most from NAT, while rare melanomas still have a worse response. Other ongoing studies and more mature data are needed to confirm our findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M.F. Ribeiro: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb. All other authors have declared no conflicts of interest.
Resources from the same session
899P - Impact of COVID-19 pandemic on treatment and survival in head and neck squamous cell carcinoma (HNSCC) patients (IMPACCT Study)
Presenter: Berta Vilar Anglada
Session: Poster session 12
900P - COVID-19 in patients with head and neck cancers (HERODOTUS): An international, registry-based, cohort study
Presenter: Amanda Psyrri
Session: Poster session 12
901P - Gut microbiome metagenomics and toxicity outcomes from chemoradiation therapy in head and neck squamous cell carcinoma
Presenter: Antoine Desilets
Session: Poster session 12
902P - Cisplatin-induced ototoxicity in head and neck cancer: The patterns and prediction
Presenter: Chiaki Suzuki
Session: Poster session 12
903P - AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
Presenter: Renata Ferrarotto
Session: Poster session 12
904P - Retrospective analysis of adjuvant systemic anti-hormonal therapy for resected androgen receptor-positive (AR+) salivary duct carcinoma (SDC)
Presenter: Jetty Weijers
Session: Poster session 12
905P - Hot topics in salivary gland carcinomas treatment: An EORTC young investigator and early career investigator survey
Presenter: Luigi Lorini
Session: Poster session 12
906P - Multi-parameter flow cytometry analysis of circulating immune cell populations in recurrent/metastatic adenoid cystic carcinoma
Presenter: Samuel Rack
Session: Poster session 12
907P - Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II
Presenter: Laura Locati
Session: Poster session 12
908P - Efficacy of NOTCH inhibitors (Ni) relative to prior systemic therapy or observation in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC)
Presenter: Camilla Hoff
Session: Poster session 12